-
公开(公告)号：US11655295B2
公开(公告)日：2023-05-23
申请号：US16963067
申请日：2019-01-03
Inventor： Tongtong Xue , Qiang Li , Liang Xiao , Yuncheng Zheng , Dengnian Liu , Si Chen , Yan Hu , Lichun Wang , Jingyi Wang
IPC: C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2803 , A61K39/39558 , A61P35/00
Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs. The drugs are used for improving the activity of immune cells and enhancing the immune response, or are used for preventing and/or treating tumors, infections or autoimmune diseases.
-
公开(公告)号：US11434235B2
公开(公告)日：2022-09-06
申请号：US16981430
申请日：2019-05-06
Inventor： Tianming Wang , Chengxi Yang , Jiaqiang Cai , Wei Liu , Baolei Zhang , Qiang Tian , Shuai Song , Hao Hu , Weibiao Han , Youqiang Li , Xing Chen , Lichun Wang , Jingyi Wang
IPC: C07D417/14 , A61K45/06
Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.
-
公开(公告)号：US10159662B2
公开(公告)日：2018-12-25
申请号：US15767508
申请日：2016-12-08
Inventor： Yinong Xie , Zejin You , Zhiwen Deng , Jun Zhu , Ao Wang , Yan Feng , Dong Long , Hong Zeng , Hongmei Song , Qijun Ye , Wei Qi , Donghai Su , Lichun Wang , Jingyi Wang
IPC: A61K31/437 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/00 , A61K39/00 , A61K31/343 , A61K38/17 , A61K31/519
Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
-
4.发明公开公开(公告)号：US20230212180A1
公开(公告)日：2023-07-06
申请号：US17926763
申请日：2021-06-11
Inventor： Lei Yi , Qiang Tian , Shoujun Chen , Liqiang Song , Taijin Wang , Qian Liu , Yong Ge , Yu Yang , Huiping Chen , Hongmei Song , Jingyi Wang
IPC: C07D491/107 , C07D401/14 , C07D471/10 , C07D491/20 , A61P35/00
CPC classification number: C07D491/107 , C07D401/14 , C07D471/10 , C07D491/20 , A61P35/00
Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrazine compound, a pharmaceutical composition comprising same, and the use thereof. In particular, the present invention relates to a compound with the structure of formula (I), which exhibits a good SHP2 inhibiting activity, and can act as an efficient SHP2 inhibitor for preventing and/or treating SHP2-related diseases.
-
公开(公告)号：US11541049B2
公开(公告)日：2023-01-03
申请号：US16965450
申请日：2019-03-18
Inventor： Yongyong Wu , Jiaqiang Cai , Guangchao Zhang , Shuangshuang Duan , Chaolei Wang , Lichun Wang , Jingyi Wang
IPC: C07D403/14 , A61K31/496 , A61P7/02 , A61K31/4725 , A61K45/06 , C07D401/14 , C07D413/14 , C07D401/10
Abstract: Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.
-
Patent Agency Ranking
公开(公告)号：US20220144847A1
公开(公告)日：2022-05-12
申请号：US17431930
申请日：2020-02-11
Inventor： Zhonghui Chen , Shuangshuang Duan , Guiying Li , Runfeng Han , Qizheng Sun , Liandong Jing , Xiaojun Han , Qiang Tian , Hongmei Song , Tongtong Xue , Jingyi Wang
IPC: C07D487/08 , A61P35/00
Abstract: The present disclosure relates to a heterocyclic compound, a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof. Specifically, the compound of the present invention is represented by formula (I), and used for preventing or treating a disease or condition related to RET activity.
-
公开(公告)号：US11084847B2
公开(公告)日：2021-08-10
申请号：US16321430
申请日：2017-09-22
Inventor： Jiaqiang Cai , Qiang Tian , Mingliang Zhao , Hong Zeng , Hongmei Song , Nan Yu , Hua Deng , Wei Zhong , Long Yang , Lei Wu , Haitao Huang , Yongyong Wu , Donghai Su , Xin Zhou , Yuting Tan , Lichun Wang , Jingyi Wang
Abstract: The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with κ-opioid receptor. The polyamide compound of the invention has excellent κ-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain. The compound of the invention has higher selectivity for a κ-opioid receptor, lower addictiveness, improved pharmacokinetic properties, and improved safety (lower toxicity and/or fewer side effects), good patient compliance, and/or lesser propensity for developing tolerance, among other excellent medicinal properties.
-
公开(公告)号：US20200253971A1
公开(公告)日：2020-08-13
申请号：US16859910
申请日：2020-04-27
Inventor： Shuai Song , Jiaqiang Cai , Qiang Tian , Hong Zeng , Hongmei Song , Hanwen Deng , Zujian Tang , Xiaofan Duan , Rongrong Long , Yao Liu , Lichun Wang , Jingyi Wang
IPC: A61K31/506 , A61K31/5377 , A61P31/16
Abstract: The present invention relates to a method for prophylactically treating or treating a viral disease, comprising administering to a subject in need thereof a dihydropyrimidine compound, and the viral diseases include, but are not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).
-
公开(公告)号：US20200010570A1
公开(公告)日：2020-01-09
申请号：US16516991
申请日：2019-07-19
Inventor： Baiyong Li , Tongtong Xue , Yu Xia , Zhongmin Maxwell Wang , Liang Xiao , Lichun Wang , Jingyi Wang
Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.
-
公开(公告)号：US11667629B2
公开(公告)日：2023-06-06
申请号：US16758232
申请日：2018-12-07
Inventor： Jinming Liu , Jiaqiang Cai , Yongyong Wu , Wei Yin , Lichun Wang , Jingyi Wang
IPC: C07D417/14 , C07D451/02 , C07D413/14 , B65D85/00
CPC classification number: C07D417/14 , B65D85/70 , C07D413/14 , C07D451/02
Abstract: The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.051 seconds)
